Digital healthcare ad spend is projected at $26.2bn against $6.9bn traditional. The dam broke because of FDA scrutiny of TV…
What FDA’s Moderna flu vaccine halt means for U.S. regulatory stability
The FDA’s decision to block Moderna’s mRNA flu vaccine review, despite staff endorsements and clinical data showing over 80% efficacy,…
What FDA’s Moderna flu vaccine refusal means for biotech regulatory pathways
The FDA’s October 2023 refusal to review Moderna’s mRNA influenza vaccine over control group issues underscores regulatory hurdles for novel…
What FDA’s Regenxbio gene therapy decision means for accelerated approval standards
The FDA’s review of Regenxbio’s gene therapy for Hunter syndrome intensifies focus on biomarker validation in accelerated approvals, balancing innovation…
FDA’s IND clearance for Life Biosciences shows advancing regulatory pathways for anti-aging therapies
The FDA granted IND clearance to Life Biosciences for a first-in-human trial using cellular reprogramming to treat age-related macular degeneration.…
CardioMEMS trial data shows 33% reduction in heart failure hospitalizations
NICE’s endorsement of the CardioMEMS HF System for chronic heart failure monitoring highlights clinical evidence from the CHAMPION trial, reducing…
AI regulation in healthcare: FDA’s risk-based approach reduces errors by 15% in clinical trials
Analysis of FDA’s evolving AI oversight shows clinical evidence from studies like JAMA supports efficacy, with comparisons to EU’s MDR…
What FDA’s October 2023 draft guidance on 15-year CAR-T monitoring means for autoimmune disease patients
The FDA’s push for extended safety monitoring of CAR-T therapies in autoimmune diseases, based on oncology protocols, addresses risks like…
How Amazon One Medical’s partnership with Reperio Health improves screening adherence by 30%
Amazon One Medical collaborates with Reperio Health to integrate FDA-cleared at-home preventive screenings, enhancing early detection for conditions like cardiovascular…
What the FDA’s zorevunersen delay means for rare disease therapy approvals
The FDA’s September 2023 delay of expedited filing for zorevunersen, a Dravet syndrome treatment, underscores evidence-based regulatory rigor. This analysis…
What FDA’s digital health precertification program means for underserved patient access to AI wearables
The FDA’s updated precertification program deregulates low-risk AI devices, potentially expanding affordable wearables in underserved areas but risking health disparities…
July 2024 JAMA study shows AI reduces billing errors by 30% in healthcare admin
Analytical review of agentic AI and low-code platforms automating healthcare workflows, with evidence from recent studies on error reduction, FDA…